Treatment of Lichen Simplex Chronicus in Anatomically Sensitive Areas When Topical Agents Are Poorly Tolerated
Lichen simplex chronicus (LSC) poses a distinct management challenge when it involves anatomically sensitive areas such as the genital region. Standard topical therapy may be poorly tolerated or inadequate to achieve control in these locations, leaving patients with persistent, high-burden symptoms.
Clinical scenario
LSC involving anatomically sensitive areas such as the genital region, where topical agents are poorly tolerated. Key clinical goals include relief of vulvar pruritus and thinning of lichenified skin.
Approach overview — partial
When topical therapy is insufficient or not tolerated in this setting, the structured protocol addresses systemic biologic options targeting specific interleukin signalling pathways. The complete criteria, sequencing, and agent selection are available in the full protocol below.
References
DOI: 10.1007/s40257-025-00979-z
- In anatomically sensitive areas such as the genital region, where topical agents may be poorly tolerated, systemic treatments may be required.
- A case series of three women with vulvar LSC refractory to steroids and immunomodulators found dupilumab led to marked relief of vulvar pruritus and thinning of lichenified skin, with lesions worsening again after drug discontinuation.
- This supports the consideration of systemic biologic therapy in anatomically sensitive or treatment-refractory cases of LSC, where topical agents are poorly tolerated or insufficient for disease control, particularly in areas such as the genital region where symptom burden is high and steroid use may be limited.
- Dupilumab is undergoing phase 3 trials for LSC of the skin and genitals.
- Nemolizumab, an IL-31 receptor antibody may show promise in relieving the itch-scratch cycle in LSC, as it has a significant antipruritic effect on multiple itchy conditions beyond its effect in atopic eczema and PN.
View source ↗